Status:
COMPLETED
Study Evaluating Prevenar in High-Risk Children
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Pneumococcal Disease
Eligibility:
All Genders
2-5 years
Brief Summary
The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- High-risk children ages 2 to 5 years old
- Exclusion criteria:
- Prior administration of Prevenar
- Prior and/or concurrent administration of 23 vPs vaccine
Exclusion
Key Trial Info
Start Date :
October 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2007
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT00234338
Start Date
October 1 2005
End Date
April 1 2007
Last Update
December 10 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Frankfurt, Germany, 60590